These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review. Paul S; Ali A; Katare R J Diabetes Complications; 2020 Aug; 34(8):107613. PubMed ID: 32505477 [TBL] [Abstract][Full Text] [Related]
4. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502 [TBL] [Abstract][Full Text] [Related]
5. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Chilelli NC; Burlina S; Lapolla A Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818 [TBL] [Abstract][Full Text] [Related]
8. Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications. Du MR; Ju GX; Li NS; Jiang JL J Cardiovasc Pharmacol; 2016 Oct; 68(4):322-326. PubMed ID: 27760067 [TBL] [Abstract][Full Text] [Related]
11. Eye complications and markers of morbidity and mortality in long-term type 1 diabetes. Grauslund J Acta Ophthalmol; 2011 Feb; 89 Thesis 1():1-19. PubMed ID: 21443578 [TBL] [Abstract][Full Text] [Related]
12. Haemodynamics in microvascular complications in type 1 diabetes. Candido R; Allen TJ Diabetes Metab Res Rev; 2002; 18(4):286-304. PubMed ID: 12203944 [TBL] [Abstract][Full Text] [Related]
13. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075 [TBL] [Abstract][Full Text] [Related]
14. Endothelin-1 and diabetic complications: focus on the vasculature. Ergul A Pharmacol Res; 2011 Jun; 63(6):477-82. PubMed ID: 21292003 [TBL] [Abstract][Full Text] [Related]
15. [Pathogenesis of diabetic microangiopathy]. Caimi G; Lo Presti R Minerva Endocrinol; 1993 Jun; 18(2):49-68. PubMed ID: 8289751 [TBL] [Abstract][Full Text] [Related]
16. Oxidative stress and diabetic vascular complications. Son SM; Whalin MK; Harrison DG; Taylor WR; Griendling KK Curr Diab Rep; 2004 Aug; 4(4):247-52. PubMed ID: 15265465 [TBL] [Abstract][Full Text] [Related]
17. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Krentz AJ; Clough G; Byrne CD Diabetes Obes Metab; 2007 Nov; 9(6):781-91. PubMed ID: 17924862 [TBL] [Abstract][Full Text] [Related]
18. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Cameron NE; Eaton SE; Cotter MA; Tesfaye S Diabetologia; 2001 Nov; 44(11):1973-88. PubMed ID: 11719828 [TBL] [Abstract][Full Text] [Related]
19. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Jerums G; Panagiotopoulos S; Forbes J; Osicka T; Cooper M Arch Biochem Biophys; 2003 Nov; 419(1):55-62. PubMed ID: 14568009 [TBL] [Abstract][Full Text] [Related]
20. Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. Chandy A; Pawar B; John M; Isaac R Saudi J Kidney Dis Transpl; 2008 Nov; 19(6):924-8. PubMed ID: 18974577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]